Dentium CO., LTD (KRX:145720)
South Korea · Delayed Price · Currency is KRW 56,600
+2,800 (5.20%)
At close: Apr 16, 2026
Dentium CO., LTD Revenue
In the year 2025, Dentium CO., LTD had annual revenue of 346.45B KRW, down -15.05%. Dentium CO., LTD had revenue of 109.15B in the quarter ending December 31, 2025, a decrease of -8.07%.
Revenue
346.45B
Revenue Growth
-15.05%
P/S Ratio
0.96
Revenue / Employee
406.16M
Employees
853
Market Cap
332.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 346.45B | -61.36B | -15.05% |
| Dec 31, 2024 | 407.81B | 14.62B | 3.72% |
| Dec 31, 2023 | 393.19B | 37.32B | 10.49% |
| Dec 31, 2022 | 355.87B | 64.34B | 22.07% |
| Dec 31, 2021 | 291.53B | 61.78B | 26.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Value Added Technology | 426.42B |
| ALTEOGEN | 215.86B |
| BINEX | 168.47B |
| GC Cell | 165.52B |
| Yungjin Pharm. | 158.79B |